Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.59 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 4/20 | 0.52 |
| ▸ | MAOB | P27338 | 4/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | PNMT | P11086 | 1/20 | 0.50 |
| ▸ | CFD | P00746 | 1/20 | 0.50 |
| ▸ | F11 | P03951 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29474892 | 1.00 | HRH3 (0.59) | HRH3CD274MAOAMAOBCYP2D6 | |
| Hydrochloric Acid SCHEMBL29052776 | 0.99 | HRH3 (0.58) | HRH3CD274MAOAMAOBCYP2D6 | |
| Hydrochloric Acid SCHEMBL30515385 | 0.99 | HRH3 (0.58) | HRH3CD274MAOAMAOBCYP2D6 | |
| SCHEMBL1020646 | 0.94 | CD274 (0.61) | HRH3CD274MAOAMAOBCYP2D6 | |
| Phosphoric Acid SCHEMBL30800722 | 0.92 | HRH3 (0.52) | HRH3CD274MAOAMAOBCYP2D6 | |
| SCHEMBL29097853 | 0.92 | CD274 (0.57) | HRH3CD274MAOAMAOBCYP2D6 | |
| SCHEMBL30199675 | 0.92 | CD274 (0.57) | HRH3CD274MAOAMAOBCYP2D6 | |
| SCHEMBL3077665 | 0.91 | HRH3 (0.67) | HRH3MAOAMAOBCYP2D6HRH1 | |
| SCHEMBL29097880 | 0.86 | MAOB (0.56) | HRH3CD274MAOAMAOB | |
| SCHEMBL30199170 | 0.86 | MAOB (0.56) | HRH3CD274MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4129289-B1 | ANTI-ARRHYTHMIC PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR | JIANGSU KANION PHARMACEUTICAL CO LTD (CN) | 2024-10-09 | — | — | EP | claimed |
| CN-113456639-B | Anti-arrhythmia pharmaceutical composition and preparation method thereof | 江苏康缘药业股份有限公司 | 2024-01-26 | — | — | CN | claimed |
| US-20230135963-A1 | ANTI-ARRHYTHMIC PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR | JIANGSU KANION PHARMACEUTICAL CO., LTD. (CN) | 2023-05-04 | — | — | US | claimed |
| EP-4129289-A1 | ANTI-ARRHYTHMIC PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR | Jiangsu Kanion Pharmaceutical Co., Ltd. (CN) | 2023-02-08 | — | — | EP | claimed |
| CN-113456639-A | Anti-arrhythmia pharmaceutical composition and preparation method thereof | 江苏康缘药业股份有限公司 | 2021-10-01 | — | — | CN | claimed |
| CN-107778232-B | Tetrahydroisoquinoline salt derivative and preparation method and application of crystal thereof | 上海医药工业研究院 | 2021-05-28 | — | — | CN | claimed |
| US-20190177277-A1 | SALT DERIVATIVE OF TETRAHYDROISOQUINOLINE AND CRYSTALLINE THEREOF AND PREPARATION METHOD THEREFORE AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2019-06-13 | — | — | US | claimed |
| CN-107793356-A | A kind of salt derivative of tetrahydroisoquinoline and its preparation method and application of crystal | 上海医药工业研究院 | 2018-03-13 | — | — | CN | claimed |
| CN-107778232-A | A kind of salt derivative of tetrahydroisoquinoline and its preparation method and application of crystal | 上海医药工业研究院 | 2018-03-09 | — | — | CN | claimed |
| US-12622902-B2 | Anti-arrhythmic pharmaceutical composition and preparation method therefor | JIANGSU KANION PHARMACEUTICAL CO., LTD. (CN) | 2026-05-12 | — | — | US | disclosed |
| US-12622902-B2 | Anti-arrhythmic pharmaceutical composition and preparation method therefor | JIANGSU KANION PHARMACEUTICAL CO., LTD. (CN) | 2026-05-12 | — | — | US | disclosed |
| US-20260092063-A1 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | JAZZ PHARMACEUTICALS IRELAND LTD (IE) | 2026-04-02 | — | — | US | disclosed |
| US-12304912-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2025-05-20 | — | — | US | disclosed |
| EP-4129289-B1 | ANTI-ARRHYTHMIC PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR | JIANGSU KANION PHARMACEUTICAL CO LTD (CN) | 2024-10-09 | — | — | EP | disclosed |
| EP-0687267-B1 | PYRROLO-PYRIDINE DERIVATIVES AS LIGANDS OF DOPAMINE RECEPTOR | MERCK SHARP & DOHME (GB) | 1999-09-01 | — | — | EP | disclosed |
| EP-0873317-A1 | PYRIMIDIN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1998-10-28 | — | — | EP | disclosed |
| US-5700809-A | Pyrrolo-pyridine derivatives | MERCK SHARP & DOHME, LTD. (GB) | 1997-12-23 | — | — | US | disclosed |
| US-5688798-A | PSYCHOTIC ILLNESS SUCH AS SCHIZOPHRENIA | HOFFMANN-LA ROCHE INC. (US) | 1997-11-18 | — | — | US | disclosed |
| WO-1997013759-A1 | PYRIMIDIN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-04-17 | — | — | WO | disclosed |
| WO-1994020459-A2 | PYRROLO-PYRIDINE DERIVATIVES AS DOPAMINE RECEPTOR LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 1994-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177277-A1 | SALT DERIVATIVE OF TETRAHYDROISOQUINOLINE AND CRYSTALLINE THEREOF AND PREPARATION METHOD THEREFORE AND APPLICATION THEREOF | REN, SFPQ, AQP3 | HRH3 821/4885CD274 4421/4885MAOA 4041/4885 |
| US-12304912-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | BRAF, RAF1, NRAS | HRH3 3556/4885CD274 3609/4885MAOA 1519/4885 |
| US-12622902-B2 | Anti-arrhythmic pharmaceutical composition and preparation method therefor | CACNA1S, KCNN3, CACNA1G | HRH3 991/4885CD274 1318/4885MAOA 4411/4885 |
| US-20260092063-A1 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | BRAF, NRAS, RAF1 | HRH3 2968/4885CD274 3334/4885MAOA 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.